Liposome‐based STING agonists in combination with ICI therapy achieve better anticancer effects by trafficking diverse immune cells into the tumor, reverting the immunosuppressive microenvironment, and overcoming ICI resistance with negligible systemic side effects.373, 377, 400, 420, 421, 422. The gene discussed is STING1; the disease is neoplasm.